Xenogeneic antigen presenting cells and uses thereof

The method of any one of the preceding claims, wherein the antigen presenting cells are obtained from a species that is a swine.

The method of any one of the preceding claims, wherein the antigen presenting cells are obtained from a species that is a miniature swine.

The method of any one of the preceding claims, wherein the subject is a human.

The method of any one of the preceding claims, wherein the method triggers an immune response specific to the tumor.

The method of any one of the preceding claims, wherein the method yields an abscopal effect.

The method of any one of the preceding claims, wherein the tumor is a solid cancerous tumor.

The method of any one of the preceding claims, wherein the tumor is resistant to treatment to chemotherapy and/or treatment with an immunotherapy.

The method of any one of the preceding claims, wherein the antigen presenting cells are derived from one or more swine or miniature swine using a leukapheresis procedure, wherein the leukapheresis procedure generates a leukopak containing peripheral blood mononuclear cells, and the leukopak is further fractionated by counterflow elutriation.

The method of any one of the preceding claims, wherein the composition comprising antigen presenting cells is substantially free of pathogens.

The method of any one of the preceding claims, wherein the antigen presenting cells are obtained from swine or miniature swine of different genotypes.

The method of any one of the preceding claims, wherein the composition comprising antigen presenting cells is administered in single or multiple doses.

The method of any one of the preceding claims, wherein the composition comprising antigen presenting cells is administered via an intratumoral injection of at least about 1×106 antigen presenting cells per dose.

The method of any one of the preceding claims, wherein the composition comprising antigen presenting cells is administered via an intratumoral injection of about 1×106, about 5×106, about 10×106, about 15×106, about 20×106, about 25×106, about 30×106, about 35×106, about 40×106, about 45×106, about 50×106, about 55×106, about 60×106, about 65×106, about 70×106, about 75×106, about 80×106, about 85×106, about 90×106, about 95×106, about 10×107, about 15×107, about 20×107, about 25×107, about 30×107, about 35×107, about 40×107, about 45×107, or about 50×107 antigen presenting cells per dose.

The method of any one of the preceding claims, wherein the antigen presenting cells are substantially mature antigen presenting cells.

The method of any one of the preceding claims, wherein the antigen presenting cells are not activated or stimulated.

The method of any one of the preceding claims, wherein the composition comprises peripheral blood mononuclear cells (PBMC).

The method of any one of the preceding claims, wherein the composition comprises monocytes.

The method of any one of the preceding claims, wherein the composition comprises dendritic cells, macrophages, granulocytes, T-cells, B-cells, and/or NK cells.

The method of any one of the preceding claims, wherein the composition comprises at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or greater than about 95% PBMCs, wherein the PBMCs are mature, immature, or a combination of mature and immature PBMCs.

The method of any one of the preceding claims, wherein the composition comprises at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or greater than about 95% monocytes, wherein the monocytes are mature, immature, or a combination of mature and immature monocytes.

The method of any one of the preceding claims, wherein the subject is receiving another anti-cancer therapy.

A pharmaceutical composition suitable for intratumoral injection, wherein the pharmaceutical composition comprises antigen presenting cells obtained from one or more swine.